AtriCure, Inc.
ATRC- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001323885
In the last 90 days, AtriCure, Inc. insiders filed 0 open-market purchases and 7 sales; 251 institutions reported holding it in 13F filings for Q2 2026, worth $1.47B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:13 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $11.4M (2.1% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Revenue | $534.5M | $465.3M | $399.2M | $330.4M | $274.3M |
| Cost of revenue | $133.7M | $117.8M | $98.9M | $84.4M | $68.5M |
| Gross profit | $400.8M | $347.5M | $300.4M | $245.9M | $205.9M |
| Operating expenses | $410.2M | $387.5M | $327.1M | $288.6M | $150.7M |
| Research and development | $99.2M | $96.2M | $73.9M | $57.3M | $48.5M |
| Selling, general and administrative | $311.0M | $291.4M | $253.1M | $231.3M | $204.6M |
| Operating income | -$9.45M | -$40.0M | -$26.7M | -$42.7M | $55.2M |
| Interest expense | – | – | $6.92M | $4.99M | $4.92M |
| Income tax | $1.28M | $1.02M | $591.0K | $268.0K | $188.0K |
| Net income | -$11.4M | -$44.7M | -$30.4M | -$46.5M | $50.2M |
| EPS, basic | $-0.24 | $-0.95 | $-0.66 | $-1.02 | $1.11 |
| EPS, diluted | $-0.24 | $-0.95 | $-0.66 | $-1.02 | $1.09 |
| Weighted shares, basic | 47.8M | 47.0M | 46.3M | 45.7M | 45.1M |
| Weighted shares, diluted | 47.8M | 47.0M | 46.3M | 45.7M | 46.0M |
| Margins and growth | |||||
| Gross margin | 75.0% | 74.7% | 75.2% | 74.4% | 75.0% |
| Operating margin | -1.8% | -8.6% | -6.7% | -12.9% | 20.1% |
| Net margin | -2.1% | -9.6% | -7.6% | -14.1% | 18.3% |
| Revenue growth, year over year | +14.9% | +16.5% | +20.8% | +20.4% | +32.8% |
| Net income growth, year over year | – | – | – | −192.6% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Cash and equivalents | $167.4M | $122.7M | $84.3M | $58.1M | $43.7M |
| Short-term investments | – | $0 | $53.0M | $63.0M | $75.4M |
| Accounts receivable | $66.7M | $60.3M | $52.5M | $42.7M | $33.0M |
| Inventory | $78.5M | $75.3M | $67.9M | $45.9M | $39.0M |
| Total current assets | $322.5M | $267.8M | $266.2M | $215.2M | $196.1M |
| Goodwill | $234.8M | $234.8M | $234.8M | $234.8M | $234.8M |
| Intangible assets | $48.0M | $56.5M | $64.0M | $39.3M | $43.0M |
| Total assets | $654.2M | $609.3M | $613.9M | $585.4M | $615.3M |
| Accounts payable | $25.3M | $25.0M | $27.4M | $19.9M | $18.6M |
| Total current liabilities | $81.5M | $73.4M | $74.6M | $58.4M | $56.4M |
| Long-term debt | $61.9M | $61.9M | $60.6M | $56.8M | $59.7M |
| Total liabilities | $162.2M | $148.4M | $147.8M | $128.7M | $131.6M |
| Shareholders' equity | $491.9M | $461.0M | $466.2M | $456.8M | $483.8M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Operating cash flow | $57.3M | $12.2M | $4.48M | -$22.1M | -$13.8M |
| Capital expenditures | $9.05M | $11.5M | $12.0M | $16.9M | $9.75M |
| Free cash flow | $48.3M | $745.0K | -$7.51M | -$39.0M | -$23.5M |
| Stock-based compensation | $44.7M | $40.4M | $35.7M | $28.8M | $28.1M |
| Investing cash flow | -$14.6M | $30.2M | $21.8M | $44.0M | $23.5M |
| Financing cash flow | $1.18M | -$3.60M | -$32.0K | -$7.06M | -$7.64M |
| Net change in cash | $44.7M | $38.4M | $26.2M | $14.4M | $1.71M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 8.4% | 8.7% | 8.9% | 8.7% | 10.2% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.